Polysciences announces new bioprocessing brand ‘Kyfora Bio’
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
He has published more than 100 research papers in several prestigious national and international journals
Subscribe To Our Newsletter & Stay Updated